Immatics Dirección

Dirección controles de criterios 3/4

El CEO de Immatics es Harpreet Singh , nombrado en Jul 2019, tiene una permanencia de 5.33 años. compensación anual total es €6.38M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.07% de las acciones de la empresa, por valor de $9.69M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 3.5 años, respectivamente.

Información clave

Harpreet Singh

Chief Executive Officer (CEO)

€6.4m

Compensación total

Porcentaje del salario del CEO	7.7%
Permanencia del CEO	5.3yrs
Participación del CEO	1.1%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Harpreet Singh en comparación con los beneficios de Immatics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-€56m
Jun 30 2024	n/a	n/a	-€74m
Mar 31 2024	n/a	n/a	-€80m
Dec 31 2023	€6m	€488k	-€97m
Sep 30 2023	n/a	n/a	-€84m
Jun 30 2023	n/a	n/a	-€79m
Mar 31 2023	n/a	n/a	-€68m
Dec 31 2022	€7m	€522k	€38m

Compensación vs. Mercado: La compensación total de Harpreet($USD6.68M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.15M).

Compensación vs. Ingresos: La compensación de Harpreet ha sido consistente con los resultados de la empresa en el último año.

CEO

Harpreet Singh (49 yo)

5.3yrs

Permanencia

€6,378,000

Compensación

Dr. Harpreet Singh, Ph D., has been Non-Executive Director of Immatics N.V. since July 1, 2021 and served as its Supervisory Director since 2021 until July 1, 2021. Dr. Singh serves as Chief Executive Offi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Harpreet Singh	CEO, MD	5.3yrs	€6.38m	1.07% $ 9.7m
Toni Weinschenk	Co-Founder & Chief Innovation Officer	24.8yrs	sin datos	0.27% $ 2.5m
Arnd Christ	Chief Financial Officer	4.1yrs	sin datos	0.14% $ 1.3m
Steffen Walter	Chief Operations Officer	1.7yrs	sin datos	0.23% $ 2.1m
Edward Sturchio	General Counsel & Secretary	4.3yrs	sin datos	0.090% $ 811.2k
Carsten Reinhardt	Chief Development Officer	5.1yrs	sin datos	0.39% $ 3.5m
Cedrik Britten	Chief Medical Officer	4.4yrs	sin datos	0.19% $ 1.7m
Jordan Silverstein	Head of Strategy	no data	sin datos	0.16% $ 1.5m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	24.8yrs	sin datos	sin datos
Ephraim Hofsäß	Vice President of SEC Reporting & Accounting	less than a year	sin datos	sin datos
Lauren Schroeder	Vice President of Marketing	less than a year	sin datos	sin datos
Tamara Louw	VP of Human Resources & US Site Head	2.3yrs	sin datos	sin datos

4.3yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMTX se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Harpreet Singh	CEO, MD	3.3yrs	€6.38m	1.07% $ 9.7m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	no data	sin datos	sin datos
Michael Atieh	Independent Non-Executive Director	3.3yrs	€263.00k	0.046% $ 419.8k
Peter Chambré	Non-Executive Chairman	3.3yrs	€283.00k	0.31% $ 2.8m
Heather Mason	Independent Vice Chair of the Board of Directors	3.3yrs	€246.00k	0.046% $ 419.8k
Hidde L. Ploegh	Member of Scientific Advisory Board	4.4yrs	sin datos	sin datos
Patrick Hwu	Co-Chair of the Scientific Advisory Board	3.7yrs	sin datos	sin datos
Paul Rutherford Carter	Independent Non-Executive Director	3.3yrs	€259.00k	0.046% $ 419.8k
Cassian Yee	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gwendolyn Binder	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
Crystal Mackall	Co-Chair of the Scientific Advisory Board	4.2yrs	sin datos	sin datos
Roland Kontermann	Member of Scientific Advisory Board	4.3yrs	sin datos	sin datos

3.5yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de IMTX se considera experimentada (3.5 años de antigüedad promedio).

Immatics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V., Annual General Meeting, Jun 20, 2023

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics N.V. Announces Executive Changes

Recent updates

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million.

Immatics N.V. has filed a Follow-on Equity Offering.

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 76%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Immatics launches $110M stock offering

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Price target decreased to US$20.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Price target decreased to US$22.80

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Consensus forecasts updated

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Consensus forecasts updated

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020)

Supervisory Director Christof Hettich has left the company

Supervisory Director Christof Hettich has left the company

Consensus forecasts updated

First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020)

Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019)

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs